| Literature DB >> 23845438 |
Lesley-Ann Martin1, Mitch Dowsett.
Abstract
Prosurvival protein BCL-2 is overexpressed in estrogen receptor positive (ER(+)) breast cancer. In this issue of Cancer Cell, Vaillant and colleagues demonstrate that targeting BCL-2 with BH3 mimetics improves the response of xenografts from primary ER(+) breast tumors to endocrine therapy and reduces tamoxifen-induced endometrial hyperplasia, a strategy with potential clinical applicability.Entities:
Mesh：
Substances：
Year: 2013 PMID： 23845438 DOI： 10.1016/j.ccr.2013.06.006
Source DB: PubMed Journal: Cancer Cell ISSN： 1535-6108 Impact factor: 31.743